Amphastar Pharmaceuticals, Inc.
AMPH · FY2025 · Fiscal year ended Dec 31, 2025 · 10-K filed Feb 2026
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $720M | $732M | −1.7% |
| Operating income | $140M | $205M | −31.7% |
| Net income | $98.1M | $160M | −38.5% |
Latest quarter: Q3 2026
Form 10-Q · Three months ended Sep 30, 2026 · filed Nov 5, 2026
| $ | Q3 2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $208M | $192M | +8.2% |
| Operating income | $50.8M | $25.3M | +101% |
| Net income | $37.8M | $17.4M | +117% |
Q3 2026 dashboardQ3 2026 infographic
Questions
- What was Amphastar's revenue in FY2025?
- $720M in FY2025 (Fiscal year ended Dec 31, 2025), −1.7% vs $732M a year earlier, per its 10-K filed Feb 2026.
- Was Amphastar profitable in FY2025?
- Yes: net income was $98.1M and operating income $140M in FY2025.
- What was Amphastar's revenue in Q3 2026?
- $208M (+8.2% vs a year earlier), per its Form 10-Q filed Nov 5, 2026.